If u look from only this year's perspective then its pretty expensive ....but if u can see the longer term picture ahead then its good value ...just like people paid 150 multiples to Tesla initially or buy loss making software stocks
Closed 18.15 AUD with 2628 M traded on ASX ...seems they like it more then here
"“To deliver on our aspiration of doubling our constant currency revenue every five to six years, we
believe it is essential that we continue to grow our investment in our R&D activities. This includes
funding clinical trials for home respiratory support products and advancing the development of new
surgical technologies. We are also continuing to invest in growing our sales teams to support the
significant hospital hardware placements and our expanded offering into anesthesia. We have
already expanded our direct sales and distribution presence from 39 countries to 53 over the past
three years.
“Never before in our history have we changed clinical practice with such a significant advantage.
Our customers already have our hardware, they already have clinical experience with its use, and
they already have access to a huge amount of clinical evidence. This gives us confidence that we
can continue to build on our proven 50-year track record and reach more patients with our
respiratory therapies. We continue to be confident executing on our long-term growth opportunities,”
concluded Mr Gradon." https://stocknessmonster.com/announc...ph.nzx-397210/
Analysts had already penciled FY 23 S1 revenues as $ 673 M and NPAT of just $ 89 M ....Don't know they updated it so fast ...I am assuming it was already forecasted ...so nothing much bad happened then ...actually they guided 85-95 M ...knowing FPH it may turn out to be 98M ...which is above analysts consensus already on record for S1 of $ 88.9 M
FY 23 S1 was supposed to be worst and it turned out to be that way ....Forbar got it right along with UBS
Analysts had already penciled FY 23 S1 revenues as $ 673 M and NPAT of just $ 89 M ....Don't know they updated it so fast ...I am assuming it was already forecasted ...so nothing much bad happened then ...actually they guided 85-95 M ...knowing FPH it may turn out to be 98M ...which is above analysts consensus already on record for S1 of $ 88.9 M
FY 23 S1 was supposed to be worst and it turned out to be that way ....Forbar got it right along with UBS
Marketscreener on Thursday (I must have felt a downgrade was coming lol) had analysts saying H1 revenues 717m and npat 121m
so revenues might not be to much of a surprise but margins seem to have hurt profit big time ……like ô85m is 30% down on expectations …ouch
So what you’ve just seen and taken comfort in is a few updates ….. and they’ve gonecwith guidance for their guesswork
“ At the top of every bubble, everyone is convinced it's not yet a bubble.”
Originally Posted by winner69
Reply With Quote
Bookmarks